HomeCompareBMY vs ALLE

BMY vs ALLE: Dividend Comparison 2026

BMY yields 4.17% · ALLE yields 1.46%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALLE wins by $29.6K in total portfolio value· pulled ahead in Year 9
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
ALLE
ALLE
● Live price
1.46%
Share price
$142.89
Annual div
$2.08
5Y div CAGR
60.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$150.1K
Annual income
$68,750.97
Full ALLE calculator →

Portfolio growth — BMY vs ALLE

📍 ALLE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYALLE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + ALLE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
ALLE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
ALLE
Annual income on $10K today (after 15% tax)
$123.73/yr
After 10yr DRIP, annual income (after tax)
$58,438.32/yr
At 15% tax rate, ALLE beats the other by $24,588.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + ALLE for your $10,000?

BMY: 50%ALLE: 50%
100% ALLE50/50100% BMY
Portfolio after 10yr
$135.3K
Annual income
$54,287.31/yr
Blended yield
40.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BMY right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
ALLE
Analyst Ratings
8
Buy
15
Hold
Consensus: Hold
Price Target
$185.00
+29.5% upside vs current
Range: $180.00 — $190.00
Altman Z
4.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
ALLE buys
0
No recent congressional trades found for BMY or ALLE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYALLE
Forward yield4.17%1.46%
Annual dividend / share$2.49$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%60.6%
Portfolio after 10y$120.5K$150.1K
Annual income after 10y$39,823.66$68,750.97
Total dividends collected$91.0K$122.2K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldHold
Analyst price target$62.73$185.00

Year-by-year: BMY vs ALLE ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrALLE PortfolioALLE Income/yrGap
1$11,271$571.12$10,934$233.78+$337.00BMY
2$12,884$824.20$12,083$383.65+$801.00BMY
3$14,993$1,206.32$13,565$636.35+$1.4KBMY
4$17,839$1,797.27$15,587$1,072.29+$2.3KBMY
5$21,826$2,738.11$18,527$1,849.31+$3.3KBMY
6$27,643$4,289.31$23,123$3,299.32+$4.5KBMY
7$36,534$6,955.64$30,923$6,180.58+$5.6KBMY
8$50,861$11,770.13$45,493$12,405.53+$5.4KBMY
9← crossover$75,402$20,980.23$76,070$27,393.22$668.00ALLE
10$120,504$39,823.66$150,146$68,750.97$29.6KALLE

BMY vs ALLE: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

ALLEStock

Allegion plc manufactures and sells mechanical and electronic security products and solutions worldwide. The company offers door closers, controls, and exit devices; locks, locksets, portable locks, and key systems and services; electronic security products and access control systems; time, attendance, and workforce productivity systems; doors and door systems; and other accessories. The company sells its products and solutions to end-users in commercial, institutional, and residential facilities, including education, healthcare, government, hospitality, commercial office, and single and multi-family residential markets under the CISA, Interflex, LCN, Schlage, SimonsVoss, and Von Duprin brands. It sells its products and solutions through distribution and retail channels, such as specialty distribution, e-commerce, and wholesalers, as well as through various retail channels comprising do-it-yourself home improvement centers, on-line and e-commerce platforms, and small specialty showroom outlets. Allegion plc was incorporated in 2013 and is headquartered in Dublin, Ireland.

Full ALLE Calculator →
📬

Get this BMY vs ALLE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.